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Background: Demand for colonoscopy and EGD procedures is increasing. Impediments to performing these
examinations persist. Patients perceive these procedures as unpleasant and painful. The use of suboptimal sed-
atives results in inefficiency in endoscopy practices. Improving sedation methods utilizing precise control of pre-
ferred sedatives may increase patient satisfaction and practice efficiency.
Objective: Our purpose was to demonstrate the feasibility of computer-assisted personalized sedation (CAPS)
for facilitating the precise administration of propofol by endoscopist/nurse teams, achieving minimal to moder-
ate sedation in subjects undergoing routine endoscopies.
Design: Open label, single-center studies.
Setting: Endoscopy clinics in Charlottesville, Virginia, and Gent, Belgium.
Subjects: Twenty-four adults per center; 12 colonoscopies, 12 EGDs.
Interventions: Propofol sedation with CAPS by endoscopist/registered nurse care teams.
Main Outcome Measurements: Sedation level measured by modified observer’s assessment of alertness/se-
dation (MOAA/S), recovery time measured from endoscope removal until Aldrete R 12, dosage of propofol,
oxygen saturation, and safety assessments.
Results: Subjects responded to mild tactile and verbal stimuli MOAA/S Z 5, 4, 3, or 2) 99% of the time. Mean
propofol doses in the United States and Belgium were 65.4 and 72.1 mg, respectively. Mean recovery times were
29 and 10 seconds, respectively. Oxygen desaturation occurred in only 6% of subjects. No device-related adverse
events occurred.
Limitation: Open-label design.
Conclusions: Using CAPS, the endoscopist/nurse teams precisely controlled the administration of propofol
achieving minimal to moderate sedation in subjects undergoing colonoscopy and EGD procedures. Mean pro-
pofol dosage was low and post-procedure recovery times were rapid. The device performed well when operated
by the endoscopist/nurse team, with no device-related adverse events.
Colorectal cancer is the third most common cancer diag-
nosed in theUnited States. The AmericanCancer Society es-
timated that in 2007 about 112,000 new cases of colon
cancer and 41,000 new cases of rectal cancer would be de-
tected and, that of these, about 52,000 individuals would
die of this disease.1 Despite these data, the perception
that these procedures are unpleasant and painful dissuade
many patients from having a colonoscopy. Further, practice
inefficiency in endoscopy centers resulting from the use of
suboptimal sedatives can result in significant wait times for
those patients wishing to have the procedure.
In recent years, the number of routine endoscopy pro-
cedures performed has grown substantially, due to an
aging population, increased subject awareness of the ben-
efits of cancer screening, and revised reimbursement pol-
icies for colonoscopy.2,3 The demand for procedures has
exceeded the ability of endoscopists to screen patients
in a timely manner, and patient wait times of 3 to 6
months are not uncommon.4 Based on a National Health
Abbreviations: ASA, American Society of Anesthesiologists; CAPS, com-
puter-assisted personalized sedation; CSSI, clinician satisfaction with
sedation instrument; MOAA/S, modified observer’s assessment of alert-
ness/sedation; NIBP, noninvasive blood pressure; PSSI, patient satisfac-
tion with sedation instrument.
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Interview Survey, it has been estimated that less than 30%
of adults aged 50 and older currently undergo routine co-
lorectal screening by colonoscopy.5 The American Cancer
Society has sought to increase these rates and has estab-
lished the goal that 75% of eligible individuals be screened
by the year 2015.6 Thus, the demands for routine endos-
copy procedures are expected to continue to increase.
One method of reducing these growing backlogs in
screening is to improve the throughput at endoscopy cen-
ters via practice efficiency.7 Increased practice efficiency
may be achieved by reducing the time patients spend in
the recovery room by changing sedation practice. The cur-
rent standard of care for sedation includes the adminis-
tration of a combination of anxiolytic drugs, such as
midazolam or diazepam, and analgesic drugs, usually fen-
tanyl or meperidine.8,9 These drugs, however, are associ-
ated with nausea, suboptimal drug clearance, and long
half-lives, resulting in increased time spent in the recovery
room.7
In patients undergoing routine endoscopy procedures,
the rapid action and short half-life of propofol offers an ex-
cellent sedative state and early recovery.10,11 While it has
guidelines for sedation by non-anesthesiologists, the
American Society of Anesthesiologists (ASA), as well as
the American Association of Nurse Anesthetists, recom-
mends the administration of propofol only by individuals
trained in general anesthesia.12 Due to the shortage of an-
esthesiologists and nurse anesthetists, however, it is clear
that too few of these professionals are available to support
propofol use in routine endoscopy procedures.13,14 More-
over, propofol administration by anesthesiologists is not
cost effective for these procedures, and many third-party
payers are eliminating payment for the services of anes-
thesia personnel.15
Computer-assisted personalized sedation (CAPS) is
a novel approach to propofol sedation. It integrates a suite
of patient monitors with computer-controlled propofol
delivery to enable precise control of sedation. These feasi-
bility studies illustrate the capability of CAPS for enabling
an endoscopist/nurse team to administer propofol seda-
tion during colonoscopy and EGD procedures.
METHODS
Description of the CAPS device
SEDASYS (Ethicon Endo-Surgery, Inc, Cincinnati, OH) is
an investigational CAPS device. It integrates the monitor-
ing of pulse oximetry, capnometry, EKG, noninvasive
blood pressure (NIBP), and patient responsiveness, with
oxygen and propofol delivery. SEDASYS is compliant
with relevant sections of the ASA guidelines on sedation/
analgesia by non-anesthesiologists16 and the dosing guide-
lines in propofol’s package insert. It facilitates the titration
of sedation to the desired clinical effect by automatically
calculating and delivering a loading dose for every change
in propofol infusion rate, and its as-needed function en-
ables supplemental doses of sedative to treat transient ep-
isodes of discomfort. SEDASYS incorporates restrictions in
infusion rates and infusion rate increases tied to the sub-
ject’s response to mild verbal and tactile stimuli. Addition-
ally, it responds to early signs of oversedation, as indicated
by apnea or hypoxemia, by stopping delivery of propofol
and increasing oxygen delivery, as well as by prompting
the subject to take a deep breath. Upon resumption of
normal ventilatory function, it resumes the delivery of pro-
pofol at a reduced infusion rate, or recommends a reduced
rate and requires the endoscopist/nurse team to resume
delivery of sedative. SEDASYS cannot initiate an increase
in infusion rate or any additional dosing of propofol at
any time.
Study design
These were 2 open-label, single-center studies, at Char-
lottesville Medical Research, Charlottesville, Virginia, and
at Ghent University Hospital, Gent, Belgium. Each center
enrolled 24 adult (R 18 years) subjectsd12 for colono-
scopy and 12 for EGD procedures. All subjects were ASA
Class I, II, or III. Exclusion criteria included allergy or in-
ability to tolerate study medications (including an allergy
to eggs), a baseline oxygen saturation! 90% (on room
air), women who were pregnant or nursing, or participa-
tion in a clinical trial within the previous 30 days. The
study design was approved by the institutional review
board/ethics committee of each institution and the Food
and Drug Administration/Competent Authority of each
country, and all subjects provided written informed
consent.
Subjects for colonoscopy were given a colon-cleansing
preparation the evening before the examination, and all
subjects consumed nothing by mouth up to 4 hours be-
fore the study procedure. Subjects who were healthy
Capsule Summary
What is already known on this topic
d Propofol is the preferred sedative for procedural
sedation, but it is approved for administration only by
persons trained in the administration of general
anesthesia.
What this study adds to our knowledge
d In 2 open-label, single-center studies, each with 24
subjects undergoing elective GI endoscopy and
colonoscopy, computer-assisted personalized sedation
facilitated propofol administration by the endoscopist-
nurse team, achieving a level of sedation that was
satisfactory to both clinicians and patients.
d Mean propofol dosage was low, recovery times were
rapid, and no device-related adverse events occurred.
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and! 65-years old were administered a single dose of 50
to 100 mg fentanyl, whereas subjects who were frail, debil-
itated, and/or R 65-years old were administered a single
dose of 25 to 50 mg fentanyl. Three minutes later, propofol
was initiated at 75 mg/kg/minute and then titrated to de-
sired clinical effect, with infusion rate increases/decreases,
and/or the use of an as-needed dose of 0.25 mg/kg. Propo-
fol infusion was stopped or reduced during withdrawal of
the endoscope as determined by the anticipated length of
the withdrawal.
The level of sedation was determined by a modified ob-
server’s assessment of alertness/sedation scores (MOAA/S)
every 2 minutes (Table 1). Aldrete score was assessed ev-
ery minute following removal of the endoscope, with re-
covery time measured as the time from endoscope
removal to Aldrete R 12. All vital signs and propofol dos-
ing were captured electronically. Psychomotor tests were
performed at baseline, on attainment of Aldrete R 12,
and after an additional 30 minutes. Clinician and subject
satisfaction were assessed by 2 newly validated measures,
the Clinician Satisfaction with Sedation Instrument (CSSI)
and the Patient Satisfaction with Sedation Instrument
(PSSI).17,18
Safety assessments included incidence and duration of
desaturation (SpO2! 90% for O 15 seconds), incidence
and duration of apnea (lack of ventilatory activity forO 30
seconds), incidence of bradycardia (heart rate! 50 bpm
for R 30 seconds), incidence of hypotension (systolic
blood pressure! 90 mm Hg for 2 or more consecutive
NIBP readings taken approximately 3 minutes apart). All
decisions made by SEDASYS were evaluated by anesthesi-
ologists following the procedures.
Adverse events, concomitant medications, number of
polyps identified, and concomitant procedures were
recorded.
Statistical methods
Continuous safety and effectiveness parameters were
summarized by presenting the number of subjects,
mean, standard deviation, minimum, and maximum by
procedure (EGD or colonoscopy), and by center (U.S.
or Belgium). Tabulation of categorical parameters by pro-
cedure included counts and percentages. Propofol infu-
sion rate was assessed for total procedure, intubation
(from endoscope ‘‘in’’ to cecum/duodenum), and with-
drawal (from cecum/duodenum to endoscope ‘‘out’’).
RESULTS
Subject demographics
The demographic characteristics of the United States
and Belgian subjects are shown in Table 2. The 2 groups
of subjects were sufficiently matched in age, gender, ASA
classification, weight, and body mass index.
Sedation level
Subject alertness was assessed at 2-minute intervals by
MOAA/S scoring. Figure 1 shows that at 99% of the mea-
sures, subjects were responsive to mild tactile and/or ver-
bal stimuli (MOAA/S Z 5, 4, 3, or 2). In only 1% of
measures did subjects require a trapezius squeeze to gen-
erate a response (MOAA/SZ 1) and at no time was a sub-
ject nonresponsive to a trapezius squeeze (MOAA/SZ 0).
It would be reasonable to assume that the intended
level of sedation is equivalent to the mean MOAA/S score
for each subject. Figure 2 represents the individual mean
MOAA/S values for all 48 subjects included in the U.S.
and Belgian centers. It is important to note that all subject
values are on the left half of the MOAA/S graph,
TABLE 1. Modified observer’s assessment of alertness/
sedation (MOAA/S)
MOAA/S
Score Description
ASA sedation
continuum
5 Responds readily to name
spoken in normal tone
(awake)
Minimal sedation
4 Lethargic response to
name spoken in
normal tone
Moderate sedation
3 Responds after name
called loudly or repeatedly
Moderate sedation
2 Purposeful response to
mild prodding or mild
shaking
Moderate sedation
1 Responds to trapezius
squeeze (includes purposeful
and reflexive withdrawal)
Deep sedation
0 No response to painful
stimulus (trapezius squeeze)
General anesthesia
TABLE 2. Subject demographics
US
subjects
Belgian
subjects Total
Colonoscopy/EGD 12/12 12/12 24/24
ASA Class I/II/III 2/15/7 11/9/4 13/24/11
Males/females 11/13 12/12 23/25
Median age year
(range)
54 (31-70) 53 (21-73) 54 (21-73)
Median weight
kg (range)
80 (56-107) 74 (45-109) 77 (45-109)
Median BMI kg/m2
(range)
28 (21-41) 26 (20-39) 27 (20-41)
BMI, Body mass index.
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demonstrating that the endoscopist was targeting minimal
to moderate sedation while using CAPS.
Drug dosing
For colonoscopy, the mean propofol dosage needed to
achieve and maintain desired sedation levels was 82.7 mg
(range 50 - 110 mg) in the United States and 102.5 mg
(range 60 - 150 mg) in Belgium. For EGD, the mean pro-
pofol dosage was 49.2 mg (range 20 - 80 mg) in the United
States and 41.7 mg (range 20 - 60 mg) in Belgium. The
mean average propofol infusion rates for the procedure,
intubation portion of the procedure, and withdrawal por-
tion of the procedure are shown in Table 3 for both colo-
noscopy and EGD. The mean fentanyl dosage was 89 mg
(range 25 - 100 mg) in the United States and 67 mg (range
25 - 100 mg) in Belgium.
Recovery and procedure times
The mean recovery times, from endoscope ‘‘out’’ to Al-
dreteR 12, in the United States and Belgium were 29 and
10 seconds, respectively, for colonoscopy, and 28 and 10
seconds, respectively, for EGD. The mean procedure
times, from endoscope ‘‘in’’ to endoscope ‘‘out,’’ in the
United States and Belgium were 9 minutes 29 seconds
(range 6:30 - 14:03) and 11 minutes 51 seconds (range
5:49 - 20:04), respectively, for colonoscopy, and 2 minutes
29 seconds (range 1:34 - 4:10) and 2 minutes 44 seconds
(range 1:41 - 4:28), respectively, for EGD.
Subjective assessments
In the United States, 11 of 24 (46%) subjects had little
or no recall of the procedure, whereas 13 (54%) had
much or complete recall. In Belgium, 8 of 24 (33%) sub-
jects had little or no recall of the procedure, whereas 16
(67%) had much or complete recall. In both United States
and Belgian centers, the level of satisfaction with CAPS
among both endoscopists and subjects was high (Table 4).
Postprocedure assessments by the anesthesiologist at
each study site agreedwith all clinically significant decisions
made by SEDASYS (over 21,000 device decisions).
Safety assessments
Oxygen desaturation occurred in only 3 of 48 (6%) sub-
jects; the mean duration of desaturation was 26 seconds
in the United States (range 25 - 28 seconds) and 31 seconds
in Belgium (range 16 - 45 seconds). Of the 48 subjects, 18
(38%) experienced at least one episode of apneaO 30 sec-
onds; the mean time to recovery of respiration was 6 sec-
onds (range 1 - 37 seconds) in the United States, and 6
seconds (range 2 - 30 seconds) in Belgium. No subjects ex-
perienced hypotension or bradycardia. Therewas no neces-
sity for oral airways or other ventilatory support measures.
There were no device- or drug-related adverse events.
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Figure 1. Individual MOAA/S scores for all 48 subjects.
0
5
10
15
20
25
5 4 3 2 1 0MOAA/S
M
e
a
n
 
V
a
l
u
e
 
p
e
r
 
S
u
b
j
e
c
t
s
US
Belgium
Sedation
Level
Minimal
Sedation
Moderate
Sedation
Deep
Sedation
General
Anesthesia
Figure 2. Mean MOAA/S scores for all 48 subjects.
TABLE 3. Propofol infusion rate summary
United States, mean* ± SD (range) Belgium, mean* ± SD (range)
Colonoscopy EGD Colonoscopy EGD
Procedure infusion rate (mg/kg/min) 55.4  8.8 (42.7-70.2) 51.2  17.6 (3.9-66.4) 68.0  14.4 (44.5-88.1) 64.8  6.0 (53.2-72.9)
Intubation infusion rate (mg/kg/min) 72.3  8.4 (47.9-81.8) 60.9  20.4 (5.0-75.5) 80.3  9.4 (65.0-97.0) 73.3  5.4 (55.7-75.5)
Withdrawal infusion rate (mg/kg/min) 12.1  8.0 (0.0-27.4) 14.6  13.3 (0.0-47.6) 29.8  27.7 (0.0-90.9) 41.9  17.3 (14.3-72.9)
*The mean and range of the average infusion rate for each subject.
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DISCUSSION
CAPS is a novel approach to sedation that integrates
continuous physiological monitoring with the delivery of
propofol through a computer interface to facilitate precise
control of level of sedation. SEDASYS, the CAPS device
used in this study, is compliant with relevant sections of
the ASA guidelines on sedation/analgesia by non-anesthe-
siologists16 and the dosing guidelines in propofol’s pack-
age insert. Using SEDASYS, the endoscopist/nurse team
precisely controlled the administration of propofol to
achieve minimal to moderate sedation in subjects under-
going routine endoscopy procedures.
In this study, all 48 subjects undergoing colonoscopy or
EGD procedures were moderately sedated, with mean sub-
ject MOAA/S scores of 3 (nZ 2), 4 (nZ 16), and 5 (nZ 30).
The endoscopist/nurse teams achieved the desired levels of
sedation with substantially lower dosages of propofol than
those reported with the nurse-administered propofol seda-
tion (NAPS) trial.19 In both the U.S. and Belgian centers, the
mean propofol dosages (65.5 and 72.1 mg, respectively)
were about one third of the mean dosage reported in the
NAPS study. The mean propofol infusion rates achieved
with CAPS (55.4 mg/kg/min in United States and 66.4 mg/
kg/min in Belgium) were well within the dosing guidelines
in propofol’s package insert (‘‘most patients require an in-
fusion of 25 to 75 mg/kg/min’’).
In addition, use of SEDASYS allowed for more precise
control of the propofol infusion. For example, the mean
average infusion rate for colonoscopy during withdrawal
of the endoscope was less than 25% of the rate needed
during intubation of the colon. This moment-to-moment
control of propofol infusion led to very rapid (! 30 sec-
onds) postprocedure recovery from sedation. Validated
physician and patient satisfaction with sedation scores
showed that both endoscopists and subjects were highly
satisfied with the level of sedation. Anecdotally, subjects
who had had prior colonoscopy with opiates and benzodi-
azepines were highly satisfied with the rapid recovery, and
in particular with the lack of sedation ‘‘hangover’’ nor-
mally expected to last several hours postprocedurally.
SEDASYS performed as designed, reducing or stopping
propofol infusion at the first signs of oversedation. The in-
cidence of oxygen desaturation was very low, with only 6%
of subjects experiencing at least one event. In regard to
apnea, it is likely that SEDASYS detects apnea more sensi-
tively than clinical observation, suggesting that previously
published assessments of apnea incidence in other studies
may be too low. Thus, although 38% of subjects experi-
enced at least one event, this incidence was probably
comparable to those reported elsewhere.20 This was cor-
roborated by postprocedure review by anesthesiologists
who agreed with all clinically significant decisions made
by the device. It is important to note that in this feasibility
study, there was no necessity for oral airways or other ven-
tilatory interventions, and there were no device-related
adverse events.
In this study, the U.S. and Belgium data were compara-
ble, thus demonstrating the reproducibility and consistency
of the results obtained by the use of CAPS across 2 countries
and 2 practice settings, viz, an outpatient private practice
setting and an academic institution. The results reported
here are also consistent with previous studies of propofol
use, regarding subject comfort and satisfaction, quicker
subject recovery, and less nausea and vomiting.10,21-29
These factors are important for improving practice efficien-
cies, permitting more procedures to be completed each
day, and potentially increasing capacity to meet the rising
demands for routine endoscopy procedures.29 In addition,
a recent study conducted in a large community-based gas-
troenterology practice reported an increased rate of ade-
noma detection among physicians who had longer mean
colonoscopy withdrawal times.30 Because recovery from
propofol sedation is extremely rapid, the use of CAPS may
allow endoscopists to be more thorough withdrawing the
endoscope, without extending the length of the procedure.
CAPS may improve both practice efficiency and quality of
colonoscopy screening by reducing the time for patient
recovery, albeit in the procedure or recovery rooms.
In conclusion, the findings reported here demonstrate
the feasibility of CAPS to facilitate propofol sedation by en-
doscopist/nurse teams in subjects undergoing colono-
scopy and EGD procedures. Further studies are needed
with SEDASYS to fully establish the value of CAPS com-
pared to the current sedation practice of benzodiazepines
combined with opioids.
TABLE 4. Endoscopist and subject satisfaction with the CAPS device
United States Belgium
Endoscopist satisfaction* mean  SD 99.4  1.5 85.9  8.4
Subject satisfactiony mean  SD 95.3  7.6 90.4  10.0
*Using the clinician satisfaction with sedation instrument (CSSI), in which 0Z very dissatisfied and 100Z
very satisfied.
yUsing the patient satisfaction with sedation instrument (PSSI), in which 0Z very dissatisfied and 100Z
very satisfied.
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